The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.
In patients with IgA nephropathy, the IgA protein accumulates and damages the filtering part of the kidney, or glomerulus. Endothelin and angiotensin II contribute to the pathogenesis of this condition through different pathways. The phase 3 PROTECT trial compared sparsentan, a dual endothelin and angiotensin II receptor blocker, with irbesartan, an angiotensin II receptor blocker, in patients with IgA nephropathy.
Bardoxolone methyl is an activator of the Keap1-Nrf2 pathway, which helps protect cells from stresses caused by reactive oxygen species and electrophiles. A previous phase 3 trial demonstrated that BARD improves kidney function, but the trial was terminated prematurely because of an imbalance in heart failure between BARD and placebo groups.
The phase 2b ZENITH-CKD trial assessed the effects of zibotentan, a selective endothelin receptor antagonist, when administered concomitantly with an SGLT2 inhibitor in patients with CKD. A low dose of zibotentan combined with the SGLT2 inhibitor dapagliflozin resulted in a clinically relevant 27% reduction in albuminuria compared with dapagliflozin alone, with an acceptable tolerability profile.
Individuals with advanced CKD have the best chance for a longer and healthier life if they receive a kidney transplant, but barriers to transplantation exist. A team in Ontario, Canada conducted a clinical trial to test whether a multi-component intervention that targets many of these barriers can help potentially transplant-eligible patients with advanced CKD complete key steps toward receiving a kidney transplant.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Royal Mail's Christmas stamps 2023: How Yorkshire inspired Royal Mail's Christmas 2023 stampsA Yorkshire artist has spoken of his delight after his work was chosen for the Royal Mail’s Christmas stamps.
Read more »
Are results from clinical trials in kidney transplant recipients applicable to the real world?Investigators recently examined the extent to which participants in clinical trials related to kidney transplantation are similar to individuals undergoing transplantation in the United States. The research will be presented at ASN Kidney Week 2023 November 1–5.
Read more »
Scientists create the most complete atlas of the human fetal kidney to dateScientists have examined the gene expression patterns of single cells from 5 human fetal kidneys to create the most complete atlas of the fetal kidney to date. The research will be presented at ASN Kidney Week 2023 November 1–5.
Read more »
County-level structural racism may affect mortality rates in people with kidney failureA new analysis indicates that county-level structural racism is a significant determinant of death among individuals with kidney failure. The research will be presented at ASN Kidney Week 2023 November 1–5.
Read more »
Wildfire air pollution may increase risks of hospitalization and death among patients on dialysisIn analyses of data from western US states, increases in wildfire-related air pollution around dialysis clinics were linked to higher rates of hospitalizations and deaths among patients. The research will be presented at ASN Kidney Week 2023, November 1–5.
Read more »
Different antibiotics' effects on gut microbes may impact hypertensive organ damageNew research in rodents indicates that altering gut microbes may affect the development of organ damage associated with hypertension. The findings will be presented at ASN Kidney Week 2023, November 1–5.
Read more »